Exelixis (EXEL) Change in Acquisitions & Divestments (2010 - 2026)
Exelixis (EXEL) recorded quarterly Change in Acquisitions & Divestments of $225.1 million in Q2 2026, up 18.9% quarter-over-quarter from $189.3 million in Q1 2026, and down 13.05% on a YoY basis from $258.9 million in Q2 2025.
Exelixis (EXEL) Change in Acquisitions & Divestments (2010 - 2026) Analysis & Trends
Exelixis' Change in Acquisitions & Divestments history runs 17 years deep, the most recent figure standing at $225.1 million for Q2 2026.
- In Q2 2026, Change in Acquisitions & Divestments fell 13.05% year-over-year to $225.1 million; the TTM figure through Apr 2026 stood at $989.1 million (up 13.98% YoY), while the FY2026 annual figure was $1.0 billion, up 16.59% from the prior year.
- Change in Acquisitions & Divestments was $225.1 million for Q2 2026 at Exelixis, up from $189.3 million in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $353.1 million in Q3 2025 to a low of $153.5 million in Q4 2023.
- Historically, Change in Acquisitions & Divestments has averaged $248.7 million across 5 years, with a median of $238.0 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Change in Acquisitions & Divestments slumped 46.18% in 2024, then jumped 64.02% in 2025.
- A 5-year view of Change in Acquisitions & Divestments shows it stood at $238.0 million in 2022, then slumped by 35.5% to $153.5 million in 2023, then rose by 9.07% to $167.4 million in 2024, then surged by 32.31% to $221.5 million in 2025, then increased by 1.63% to $225.1 million in 2026.
- The last three Change in Acquisitions & Divestments figures came in at $225.1 million (Q2 2026), $189.3 million (Q1 2026), and $221.5 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Exelixis | 13.61 Bn | 12.83 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 225.13 Mn |
| Apr 3, 2026 | 225.13 Mn |
| Jan 2, 2026 | 189.34 Mn |
| Jan 2, 2026 | 189.34 Mn |
| Oct 3, 2025 | 221.51 Mn |
| Oct 3, 2025 | 221.51 Mn |
| Jul 4, 2025 | 353.10 Mn |
| Jul 4, 2025 | 353.10 Mn |
| Apr 4, 2025 | 258.92 Mn |
| Apr 4, 2025 | 258.92 Mn |
| Jan 3, 2025 | 226.16 Mn |
| Jan 3, 2025 | 226.16 Mn |
| Sep 27, 2024 | 167.42 Mn |
| Sep 27, 2024 | 167.42 Mn |
| Jun 28, 2024 | 215.28 Mn |
| Jun 28, 2024 | 215.28 Mn |
| Mar 29, 2024 | 268.45 Mn |
| Mar 29, 2024 | 268.45 Mn |
| Dec 29, 2023 | 153.49 Mn |
| Dec 29, 2023 | 153.49 Mn |